About ten years ago, the first results of the so-called “Bangladesh regimen”, a short regimen
lasting nine months instead of 20 months, revolutionized multidrug-resistant tuberculosis …

Rationale: Improving treatment outcomes while reducing drug toxicity and shortening the
treatment duration to∼ 6 months remains an aspirational goal for the treatment of multidrug …

Multidrug-resistant (MDR) tuberculosis (TB) is a threat to global TB control, as suboptimal
and poorly tolerated treatment options have resulted in largely unfavourable outcomes for …

ABSTRACT The 2018 World Health Organization (WHO) treatment guidelines for multidrug-
/rifampicin-resistant tuberculosis (MDR/RR-TB) give preference to all-oral long regimens …

We assessed the effectiveness and safety of standardised, shorter multidrug-resistant
tuberculosis (MDR-TB) regimens by pooling data from observational studies. Published …

Rationale: Based on expert opinion, the global guidelines for management of multidrug-
resistant tuberculosis impose lengthy and often poorly tolerated treatments. Objectives: This …

Background In contrast to drug-sensitive tuberculosis, the guidelines for the treatment of
multi-drug-resistant tuberculosis (MDR-TB) have a very poor evidence base; current …

Multidrug-resistant tuberculosis (MDR-TB) is a major public health challenge, with an
estimated 480 000 new cases emerging globally each year [1]. Treatment success rates …

Abstract In December 2022 World Health Organization released a new treatment for
multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) guideline. The main …

Objective: To compare the effectiveness of second line injectables containing shorter
(duration 9–12 months) and longer treatment regimens (LTR, duration≥ 20 months) among …